Mabcure Inc. (MBCI)

Overview

MabCure Inc. is a development stage company focused on the pioneering field of cancer diagnostics and targeted therapeutics. It operates with a dedication to advancing its proprietary antibody technology for the early detection of various cancers, alongside developing specific cancer therapeutics. Initially known as Smartec Holdings, Inc., the company underwent a rebranding in January 2008, changing its name to MabCure Inc. This rebranding was a strategic move to better represent its shifted focus towards cancer research and antibody technology. Established in 2006, MabCure has its headquarters located in White Plains, New York, marking its presence as a significant player in the biotechnology industry focused on cancer detection and treatment solutions.

Products and Services

MabCure Inc. specializes in crafting innovative solutions for the early detection and treatment of cancer. Its product and service offerings are centered around the use of proprietary technology to create monoclonal antibodies that are targeted against specific cancer markers, laying the groundwork for both diagnostic tools and therapeutic products.

• Development of Monoclonal Antibodies for Early Cancer Detection: MabCure’s core endeavor lies in the generation of monoclonal antibodies designed to recognize specific antigens associated with various forms of cancer. This approach aims at the early detection of cancer, potentially before the manifestation of symptoms, thereby enabling timely and more effective treatment strategies.
• Creation of Specific Therapeutics Against Cancer: Leveraging its proprietary antibody technology, MabCure is also involved in developing targeted therapeutic options for cancer treatment. These therapeutics are engineered to directly attack cancer cells by binding to specific cancer markers, offering a promising avenue for personalized medicine and treatment modalities with potentially fewer side effects compared to conventional methods.